Becton Dickinson vs Biconomy

Side-by-side comparison of AI visibility scores, market position, and capabilities

Becton Dickinson leads in AI visibility (69 vs 20)
Becton Dickinson logo

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
B69
Category Rank
#120 of 290
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
76
Gemini
63

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile
Biconomy logo

Biconomy

EmergingWeb3

Web3 Transaction Infrastructure

Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
13
Perplexity
26
Gemini
13

About

Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.

Full profile

AI Visibility Head-to-Head

69
Overall Score
20
#120
Category Rank
#1
71
AI Consensus
55
stable
Trend
up
73
ChatGPT
13
76
Perplexity
26
63
Gemini
13
70
Claude
28
70
Grok
15

Key Details

Category
Enterprise
Web3 Transaction Infrastructure
Tier
Leader
Emerging
Entity Type
company
brand

Capabilities & Ecosystem

Capabilities

Only Biconomy
Web3 Transaction Infrastructure

Integrations

Only Becton Dickinson
Becton Dickinson is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.